Brief: Silexion Therapeutics Announces Additional Promising Preclinical Data For SIL-204, Demonstrating Impressive Synergy With First-Line Pancreatic Cancer Chemotherapies

Silexion Therapeutics

15/01/2025 21:03

Jan 15 (Reuters) - Silexion Therapeutics  SLXN.O :
    * SILEXION THERAPEUTICS ANNOUNCES ADDITIONAL PROMISING
PRECLINICAL
DATA FOR SIL-204, DEMONSTRATING IMPRESSIVE SYNERGY WITH
FIRST-LINE PANCREATIC CANCER CHEMOTHERAPIES
    * SILEXION THERAPEUTICS CORP - ANNOUNCES SYNERGISTIC
EFFICACY OF
SIL-204 IN PANCREATIC CANCER
    * SILEXION THERAPEUTICS CORP - COMBINATION OF SIL-204 AND
CHEMOTHERAPY REDUCES CANCER CELL CONFLUENCE
    * SILEXION THERAPEUTICS CORP - TO INITIATE PRECLINICAL
STUDIES FOR
SIL-204 IN COLORECTAL CANCER

Source text:  ID:nGNX5kXZ0q 
Further company coverage:  SLXN.O 

 ((Reuters.Briefs@thomsonreuters.com;))